BiotechTubeBiotechTube
Home/Pipeline/ARV-806

ARV-806

Pancreatic Cancer

Phase 1Active

Key Facts

Indication
Pancreatic Cancer
Phase
Phase 1
Status
Active
Company
Arvinas

About Arvinas

Arvinas is a leader in the field of targeted protein degradation, founded on groundbreaking research from Yale University. The company's PROTAC® platform enables the development of therapeutics that harness the body's natural protein disposal system to degrade disease-causing proteins, potentially addressing previously 'undruggable' targets. With multiple clinical-stage assets, strategic partnerships, and a robust discovery engine, Arvinas aims to revolutionize treatment for serious diseases in oncology and neurology.

View full company profile

Therapeutic Areas

OncologyNeurology

Other Pancreatic Cancer Drugs

DrugCompanyPhase
CPI-613 (devimistat) + HydroxychloroquineRafael HoldingsPhase 1/2
Ampligen® (rintatolimod)AIM ImmunoTechEarly Access Program
SIMBs + ImmunotherapyAdvanced MicrobubblesPre-clinical
CLS-014CLS TherapeuticsPre-clinical
SOMA PlatformCoherence NeuroPre-clinical
SON-1210Sonnet BioTherapeuticsPhase 1/2a